Read + Share
Park SJ, Chang SJ, Suh DH, Kong TW, et al. A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor,
for platinum-resistant recurrent ovarian cancer. BMC Cancer 2022;22:28.
PMID: 34980026
|
 |
|
Park SJ, Chang SJ, Suh DH, Kong TW, et al. A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor,
for platinum-resistant recurrent ovarian cancer. BMC Cancer 2022;22:28.
PMID: 34980026
|
|
|
|